Zacks Research Weighs in on ResMed’s Q2 Earnings (NYSE:RMD)

ResMed Inc. (NYSE:RMD) – Investment analysts at Zacks Research upped their Q2 2025 earnings per share estimates for shares of ResMed in a report issued on Thursday, December 5th. Zacks Research analyst R. Department now forecasts that the medical equipment provider will post earnings per share of $2.25 for the quarter, up from their previous estimate of $2.24. The consensus estimate for ResMed’s current full-year earnings is $9.34 per share. Zacks Research also issued estimates for ResMed’s Q3 2025 earnings at $2.28 EPS, Q4 2025 earnings at $2.35 EPS, FY2025 earnings at $9.08 EPS, Q2 2026 earnings at $2.33 EPS, Q3 2026 earnings at $2.48 EPS, FY2026 earnings at $9.54 EPS, Q1 2027 earnings at $2.45 EPS and FY2027 earnings at $10.48 EPS.

ResMed (NYSE:RMD) last posted its quarterly earnings data on Thursday, October 24th. The medical equipment provider reported $2.20 earnings per share for the quarter, topping analysts’ consensus estimates of $2.03 by $0.17. The firm had revenue of $1.22 billion during the quarter, compared to analysts’ expectations of $1.19 billion. ResMed had a return on equity of 25.53% and a net margin of 23.15%. The business’s quarterly revenue was up 11.1% on a year-over-year basis. During the same quarter last year, the firm earned $1.64 EPS.

Other equities research analysts have also recently issued reports about the company. Royal Bank of Canada raised their target price on ResMed from $224.00 to $232.00 and gave the company a “sector perform” rating in a research report on Friday, October 25th. Robert W. Baird upped their price target on ResMed from $280.00 to $283.00 and gave the stock an “outperform” rating in a research note on Friday, October 25th. Wolfe Research reiterated an “underperform” rating and issued a $180.00 price objective on shares of ResMed in a research note on Wednesday, September 18th. KeyCorp raised their price objective on ResMed from $251.00 to $266.00 and gave the stock an “overweight” rating in a report on Friday, October 25th. Finally, Baird R W raised ResMed to a “strong-buy” rating in a report on Tuesday, September 24th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $225.70.

ResMed Stock Performance

NYSE RMD opened at $244.63 on Monday. The stock has a 50-day simple moving average of $242.31 and a two-hundred day simple moving average of $226.81. The firm has a market capitalization of $35.91 billion, a P/E ratio of 32.40, a PEG ratio of 1.75 and a beta of 0.68. ResMed has a fifty-two week low of $162.18 and a fifty-two week high of $260.49. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.91 and a current ratio of 2.92.

ResMed Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 12th. Shareholders of record on Thursday, November 7th will be paid a $0.53 dividend. The ex-dividend date is Thursday, November 7th. This represents a $2.12 annualized dividend and a yield of 0.87%. ResMed’s payout ratio is currently 28.08%.

Insider Activity

In other ResMed news, CFO Brett Sandercock sold 1,000 shares of the company’s stock in a transaction dated Tuesday, October 8th. The shares were sold at an average price of $233.47, for a total value of $233,470.00. Following the completion of the transaction, the chief financial officer now owns 95,812 shares in the company, valued at approximately $22,369,227.64. This represents a 1.03 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Witte Jan De sold 796 shares of the stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $248.81, for a total transaction of $198,052.76. Following the completion of the transaction, the director now owns 6,723 shares of the company’s stock, valued at $1,672,749.63. This trade represents a 10.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 52,725 shares of company stock valued at $12,516,248 in the last ninety days. Company insiders own 0.71% of the company’s stock.

Institutional Trading of ResMed

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. American Trust purchased a new stake in shares of ResMed in the 3rd quarter valued at approximately $690,000. Franklin Resources Inc. boosted its holdings in ResMed by 56.5% in the 3rd quarter. Franklin Resources Inc. now owns 174,113 shares of the medical equipment provider’s stock valued at $41,909,000 after purchasing an additional 62,882 shares during the period. Tidal Investments LLC lifted its holdings in shares of ResMed by 738.4% during the 3rd quarter. Tidal Investments LLC now owns 104,938 shares of the medical equipment provider’s stock worth $25,617,000 after acquiring an additional 92,422 shares during the period. Wilmington Savings Fund Society FSB bought a new position in shares of ResMed during the 3rd quarter worth about $193,000. Finally, World Investment Advisors LLC bought a new position in ResMed during the 3rd quarter valued at about $541,000. 54.98% of the stock is owned by institutional investors and hedge funds.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.